# US 2015/0174146 A1 · Angiotensin converting enzyme inhibitors for treating optic neuropathy or congenital optic atrophy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0174146 A1
- Document ID: US20150174146A1
- Status: Published application
- Kind: A1
- Application number: 14/411,641
- Filed: 2013-06-28
- Published: 2015-06-25
- Earliest claimed: 2012-06-29
- Inventors: Raouf Rekik
- Web page: https://patentgrep.com/patent/US20150174146A1

## CPC

- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/401: Proline; Derivatives thereof, e.g. captopril
- A61K 31/403: condensed with carbocyclic rings, e.g. carbazole
- A61K 31/472: Non-condensed isoquinolines, e.g. papaverine
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61P 25/02: for peripheral neuropathies
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 39/02: Antidotes
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to an ophthalmic composition comprising at least one angiotensin converting enzyme (ACE) inhibitor and a pharmaceutically acceptable vehicle for use as an ophthalmic neuroprotector in treating an optic neuropathy or congenital optic atrophy.

## Claims

### Claim at position 1

-29. (canceled)

### Claim 30

A method for treating an optic neuropathy or congenital optic atrophy with an ophthalmic neuroprotector said method comprising administering to a person in need of such treatment an ophthalmic composition comprising at least one angiotensin converting enzyme (ACE) inhibitor and a pharmaceutically acceptable vehicle.

### Claim 31 (depends on 30)

The method according to claim 30, wherein said at least one angiotensin converting enzyme (ACE) inhibitor is fosinopril, ramipril, captopril, trandolapril, moexipril, lisinopril, quinapril, enalapril, perindopril, benazepril and mixtures thereof.

### Claim 32 (depends on 30)

The method according to claim 30, wherein said at least one angiotensin converting enzyme (ACE) inhibitor is fosinoprilate, trandolaprilate, moexiprilate, ramiprilate, quinaprilate, enalaprilate, perindoprilate and benazeprilate.

### Claim 33 (depends on 30)

The method according to claim 30, wherein said at least one angiotensin converting enzyme (ACE) inhibitor is an active metabolite of fosinopril, ramipril, captopril, trandolapril, moexipril, lisinopril, quinapril, enalapril, perindopril, benazepril and mixtures thereof.

### Claim 34 (depends on 30)

The method according to claim 30, wherein said optic neuropathy or optic atrophy is selected from the group comprising: congenital optic atrophy, ischemic optic neuropathy, inflammatory optic neuropathy, compressible optic neuropathy, infiltrative optic neuropathy, traumatic optic neuropathy, mitochondrial optic neuropathy, nutritional optic neuropathy, toxic optic neuropathy and hereditary optic neuropathy and central retinal artery occlusion.

### Claim 35 (depends on 30)

The method according to claim 30, wherein said hereditary optic neuropathy is selected from the group comprising: Leber's hereditary optic neuropathy, congenial optic atrophy and autosomal dominant optic atrophy, type Kjer.

### Claim 36 (depends on 30)

The method according to claim 30, wherein said optic neuropathy is toxic optic neuropathy due to acute methanol poisoning or ischemic optic neuropathy or inflammatory optic neuropathy or central retinal artery occlusion.

### Claim 37 (depends on 36)

The method according to claim 36, wherein said inflammatory optic neuropathy is selected from the group comprising optic neuritis, neuromyelitis optica and sarcoidosis.

### Claim 38 (depends on 36)

The method according to claim 36, wherein said ophthalmic composition is in the form of a solid or a solution.

### Claim 39 (depends on 36)

The method according to claim 36, wherein said ophthalmic composition can be administered orally, parentally, intravenously, intramuscularly, topically or by intra-ocular injection.

### Claim 40 (depends on 39)

The method according to claim 39, wherein said topically administration is by eye drops.

### Claim 41

A method to maintain or ameliorate the visual function of a person in need of such treatment, said method comprising administering to the person in need of such treatment an ophthalmic composition comprising at least one angiotensin converting enzyme (ACE) inhibitor and a pharmaceutically acceptable vehicle.

### Claim 42 (depends on 41)

The method according to claim 41, wherein said visual function is visual acuity or visual field.

### Claim 43

An ophthalmic composition comprising at least one angiotensin converting enzyme (ACE) inhibitor and a pharmaceutically acceptable vehicles.

### Claim 44 (depends on 43)

The ophthalmic, composition according to claim 43, wherein said at least one angiotensin convening enzyme (ACE) inhibitor is fosinopril, ramipril, captopril, trandolapril, moexipril, lisinopril, quinapril, enalapril, perindopril, benazepril and mixtures thereof.

### Claim 45 (depends on 43)

The ophthalmic composition according to claim 43, wherein said at least one angiotensin converting enzyme (ACE) inhibitor is an active metabolite of fosinopril, ramipril, captopril, trandolapril, moexipril, lisinopril, quinapril, enalapril, perindopril, benazepril and mixtures thereof.

### Claim 46 (depends on 43)

The ophthalmic composition according to claim 43, wherein said at least one angiotensin converting enzyme (ACE) inhibitor is fosinoprilate, trandolaprilate, moexiprilate, ramiprilate, quinaprilate, enalaprilate, perindoprilate and benazeprilate.

### Claim 47 (depends on 43)

The ophthalmic composition according to claim 43, wherein said ophthalmic composition is in the form of a solid or a solution.

### Claim 48 (depends on 43)

The ophthalmic composition according to claim 43, wherein said ophthalmic composition can be administered orally, parentally, intravenously, intramuscularly, topically or by intra-ocular injection.

### Claim 49 (depends on 43)

The ophthalmic composition according to claim 43, wherein said topically administration is by eye drops.

### Claim 50

An ophthalmic neuroprotector composition comprising at least one angiotensin converting enzyme (ACE) inhibitor and a pharmaceutically acceptable vehicle.

### Claim 51 (depends on 50)

The ophthalmic neuroprotector composition according to claim 50, wherein said at least one angiotensin concerting enzyme (ACE) inhibitor is fosinopril, ramipril, captopril, trandolapril, moexipril, lisinopril, quinapril, enalapril, perindopril, benazepril and mixtures thereof.

### Claim 52 (depends on 50)

The ophthalmic neuroprotector composition according to claim 50, wherein said at least one angiotensin converting enzyme (ACE) inhibitor is an active metabolite of is fosinopril, ramipril, captopril, trandolapril, moexipril, lisinopril, quinapril, enalapril, perindopril, benazepril and mixtures thereof.

### Claim 53 (depends on 50)

The ophthalmic neuroprotector composition according to claim 50, wherein said at least one angiotensin converting enzyme (ACE) inhibitor is fosinoprilate, trandolaprilate, moexiprilate, ramiprilate, quinaprilate, enalaprilate, perindoprilate and benazeprilate.
